Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lyra Therapeutics (LYRA)
NASDAQ:LYRA
Lyra Therapeutics (LYRA) Stock Price & Analysis
238 Followers
LYRA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.25 - $6.79
Previous Close$0.28
Volume548.62K
Average Volume (3M)3.82M
Market Cap
$17.07M
Enterprise Value-$32.17M
Total Cash (Recent Filing)$87.10M
Total Debt (Recent Filing)$37.86M
Price to Earnings (P/E)―
Beta0.43
Next Earnings
Aug 06, 2024EPS Estimate
-$0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.25
Shares Outstanding60,964,859
10 Day Avg. Volume1,361,276
30 Day Avg. Volume3,824,728
Standard Deviation0.25
R-Squared0.00001
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.21
Price to Sales (P/S)10.57
Price to Cash Flow (P/CF)-0.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-19.15
Enterprise Value/Gross Profit-20.65
Enterprise Value/Ebitda0.59
Forecast
1Y Price Target
$1.25Price Target Upside346.43% Upside
Rating ConsensusHold
Number of Analyst Covering4
Lyra Therapeutics News
Bulls Say, Bears Say
Bulls Say
Market PotentialLYR-210 has the potential to offer attractive peak US sales given the prevalence of the addressable market and need for a non-invasive therapy.
Product EfficacyThe LYR-220 nasal implant for post-surgical CRS patients showed significant improvements in the 3CS composite score, SNOT-22 score, and ethmoid sinus opacification in the Phase 2 BEACON trial.
Risk/Reward ProfileAn attractive risk/reward profile is seen headed into the imminent Phase 3 results.
Bears Say
Clinical Trial ResultsThe Phase 3 ENLIGHTEN-1 trial for LYR-210 in surgically naïve chronic rhinosinusitis (CRS) patients showed consistent failures across endpoints.
Financial PerformanceLyra’s limited cash-on-hand won’t be sufficient to fully fund ENLIGHTEN-2, thus it’s prudent to discount the current cash per share.
Stock RatingFollowing the announcement that Lyra’s ENLIGHTEN-1 Ph3 failed, the stock is downgraded to Underperform from Buy.
---
Ownership Overview
30.89% Insiders
3.26% Mutual Funds
57.18% Other Institutional Investors
8.67% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
LYRA FAQ
What was Lyra Therapeutics’s price range in the past 12 months?
Lyra Therapeutics lowest stock price was $0.25 and its highest was $6.79 in the past 12 months.
What is Lyra Therapeutics’s market cap?
Currently, no data Available
When is Lyra Therapeutics’s upcoming earnings report date?
Lyra Therapeutics’s upcoming earnings report date is Aug 06, 2024 which is in 33 days.
How were Lyra Therapeutics’s earnings last quarter?
Lyra Therapeutics released its earnings results on Apr 30, 2024. The company reported -$0.35 earnings per share for the quarter, missing the consensus estimate of -$0.262 by -$0.088.
Is Lyra Therapeutics overvalued?
According to Wall Street analysts Lyra Therapeutics’s price is currently Undervalued.
Does Lyra Therapeutics pay dividends?
Lyra Therapeutics does not currently pay dividends.
What is Lyra Therapeutics’s EPS estimate?
Lyra Therapeutics’s EPS estimate is -$0.33.
How many shares outstanding does Lyra Therapeutics have?
Lyra Therapeutics has 60,964,860 shares outstanding.
What happened to Lyra Therapeutics’s price movement after its last earnings report?
Lyra Therapeutics reported an EPS of -$0.35 in its last earnings report, missing expectations of -$0.262. Following the earnings report the stock price went up 1.744%.
Which hedge fund is a major shareholder of Lyra Therapeutics?
Among the largest hedge funds holding Lyra Therapeutics’s share is Perceptive Advisors LLC. It holds Lyra Therapeutics’s shares valued at 79M.
---
Lyra Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1.25 (346.43% Upside)
$1.25 (346.43% Upside)
Blogger Sentiment
Bullish
LYRA Sentiment 75%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 76.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.1%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-93.17%
12-Months-Change
Fundamentals
Return on Equity
-95.93%
Trailing 12-Months
Asset Growth
50.77%
Trailing 12-Months
Company Description
Lyra Therapeutics
Lyra Therapeutics Inc a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases. The company's technology platform, XTreo, is designed to precisely and consistently deliver medicines directly to the affected tissue for sustained periods with a single administration.
---
LYRA Stock 12 Month Forecast
Average Price Target
$1.25
▲(346.43% Upside)
Technical Analysis
Best Analysts Covering LYRA
1 Year
1 Year Success Rate
0/3 ratings generated profit
1 Year Average Return
-80.73%
reiterated a buy rating 10 months ago
Copying Louise Chen's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -80.73% per trade.
---